In conclusion, we confirmed that CDCA enhances the inhibitory effect of sorafenib on hepatocellular carcinoma cells by in vivo and in vitro experiments, which relies on the binding of CDCA to EGFR. Here, EGFR is linked to hepatocellular carcinoma.